Lithuanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
10 rezultatus
Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND
Status epilepticus is a condition in which the brain is in a state of persistent seizure. There is evidence that 30-60 minutes of persistent seizure is sufficient to damage neurons and that such a seizure is unlikely to self-terminate. Status epilepticus survivors may die soon after or
Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND
Status epilepticus is a condition in which the brain is in a state of persistent seizure. There is evidence that 30-60 minutes of persistent seizure is sufficient to damage neurons and such a seizure is unlikely to self-terminate. Status epilepticus survivors may die soon after or have
Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND
Status epilepticus is a condition in which the brain is in a state of persistent seizure. There is evidence that 30-60 minutes of persistent seizure is sufficient to damage neurons and such a seizure is unlikely to self-terminate. Status epilepticus survivors may die soon after or have
Digital electromagnetic pulse generator
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
Not applicable
INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A COMPACT DISC
Not applicable
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates generally to medical equipment for Magnetic Resonance Therapy
Transdermal delivery of medicaments with combinations of cetylated fatty ester penetrant complexes
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates in general to the field of transdermal and dermal drug delivery by using formulations of said compositions including chemical penetrants molecules, polar solvents, cream base, antioxidants and therapeutic
Compositions and methods for the treatment of moderate to severe pain
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
PRIORITY
The present application claims the benefit of Indian Provisional Patent Application No. 1840/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/050924 filed on 4 Feb. 2013, the entire disclosure of which is relied on for all purposes and is incorporated into this
Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND OF THE INVENTION
1. Field of the Invention The present invention relates to novel tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidine compounds that are antagonists of alpha V (.alpha.v) integrins, for example .alpha..sub.v.beta..sub.3 and .alpha..sub.v.beta..sub.5 integrins, their
Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a national phase of International Application No. PCT/US2014/027450 filed on Mar. 14, 2014, which claims the benefit of U.S. Provisional Application No. 61/785,478 filed on Mar. 14, 2013, each of which are incorporated herein by reference
Substituted saturated aza heterocycles as inhibitors of nitric oxide synthase
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
CROSS REFERENCE TO RELATED APPLICATION
The present invention is based on, and claims priority from 60/008,390, filed Dec. 8, 1995.
BACKGROUND OF THE INVENTION
This application is directed to inhibitors of nitric oxide synthase, and in particular substituted azacycle derivatives.
Nitric Oxide in
Cyclic amidine analogs as inhibitors of nitric oxide synthase
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND OF THE INVENTION
This application is directed to inhibitors of Nitric oxide synthase, and in particular cyclic amidines.
Nitric Oxide in Biology.
The emergence of nitric oxide (NO), a reactive, inorganic radical gas as a molecule contributing to important physiological and pathological
Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu
- Dirba 55 kalbomis
- Žolelių gydymas, paremtas mokslu
- Vaistažolių atpažinimas pagal vaizdą
- Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
- Skaitykite mokslines publikacijas, susijusias su jūsų paieška
- Ieškokite vaistinių žolelių pagal jų poveikį
- Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus
Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais
